Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A bibliometric analysis of publication trends and research hotspots in therapeutic drug monitoring for leukemia; describes the research landscape rather than testing a clinical hypothesis or reporting primary outcome data.
Preclinical mechanistic study in an animal model with no clinical trial data, demonstrating target engagement and a potential therapeutic approach requiring confirmation in human subjects.
A narrative review synthesizing mechanistic evidence and proposing cellular senescence as a unifying link between metabolic syndrome and cardiometabolic disease, without reporting new empirical data or clinical outcomes.
A mechanistic preclinical model study with supporting clinical cohort data showing KRAS mutations accelerate KMT2A::MLLT3 AML progression; limited by in vivo mouse model design and observational patient data without controlled comparison.
In vitro CRISPR-engineered model system in cord blood HSPCs demonstrating differential effects of TP53 allelic states on colony formation and chromosomal instability, but lacking clinical outcome data or in vivo validation.
This is a development and feasibility study describing the creation of a prehabilitation intervention, not yet reporting efficacy or safety outcomes; the phase III trial is ongoing and will provide the evidence needed to judge clinical impact.
Multi-omics mechanistic study in repositioned datasets with an exploratory prognostic model that fails external validation (C-index 0.55), generating hypotheses for combination therapy rather than providing actionable clinical evidence.
Retrospective cohort analysis identifying prognostic factors and comparing outcomes across therapies in NPM1-mutated AML, with clear survival endpoints but limited by single-center design and observational methodology.